Citation: Lijuan Liu, Zhihao Zhao, Feiwan Zou, Wukun Liu, Yunlong Lu. Advances in combination therapy for the treatment of estrogen receptor positive breast cancer[J]. Chinese Chemical Letters, ;2025, 36(10): 111451. doi: 10.1016/j.cclet.2025.111451 shu

Advances in combination therapy for the treatment of estrogen receptor positive breast cancer

School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

liuwukun0000@njucm.edu.cn

yunlonglu12@njucm.edu.cn

Received Date: 1 April 2025
Revised Date: 11 June 2025
Accepted Date: 12 June 2025
Available Online: 12 June 2025

Figures(13)

Breast cancer is a severe problem for women worldwide. Among them, estrogen receptor (ER) positive breast cancer accounted for 70% of total breast cancer cases, which is the most common subtype. Currently, the main therapy that targeted ER positive breast cancer is endocrine therapy. Herein, we summarized the latest research advances in combination therapies for ER positive breast cancer, focusing on ER as the main therapeutic target. The therapeutic approaches, therapeutic mechanism and resistance will be reviewed and discussed. The combinatorial targets and synergistic effects such as cell cycle-dependent kinase 4/6, phosphatidylinositol-3 kinase, histone deacetylase, bromodomain and extraterminal domain were summarized. In addition, the chemical structures of the inhibitors were also illustrated, along with a brief structure-activity relationship study. Finally, perspective and future directions on breast cancer were proposed and discussed.
- Breast cancer,
- Combination therapy,
- Endocrine therapy,
- CDK4/6 inhibitor,
- PI3K inhibitor
1. [1]
  R.L. Siegel, A.N. Giaquinto, A. Jemal, CA Cancer J. Clin. 74 (2024) 12–49. doi: 10.3322/caac.21820
2. [2]
  V. Grann, A.B. Troxel, N. Zojwalla, et al., Soc. Sci. Med. 62 (2006) 337–347. doi: 10.1016/j.socscimed.2005.06.038
3. [3]
  H. Xu, B. Xu, Chin. J. Cancer. Res. 35 (2023) 565–583. doi: 10.21147/j.issn.1000-9604.2023.06.02
4. [4]
  N. Cancer Genome Atlas, Nature 490 (2012) 61–70. doi: 10.1038/nature11412
5. [5]
  P. Eroles, A. Bosch, J.A. Perez-Fidalgo, A. Lluch, Cancer Treat. Rev. 38 (2012) 698–707. doi: 10.1016/j.ctrv.2011.11.005
6. [6]
  Y.S. Sun, Z. Zhao, Z.N. Yang, et al., Int. J. Biol. Sci. 13 (2017) 1387–1397. doi: 10.7150/ijbs.21635
7. [7]
  S. Arora, P. Narayan, C.L. Osgood, et al., Clin. Cancer Res. 28 (2022) 1072–1086. doi: 10.1158/1078-0432.ccr-21-2600
8. [8]
  F. Andre, E. Ciruelos, G. Rubovszky, et al., N. Engl. J. Med. 380 (2019) 1929–1940. doi: 10.1056/nejmoa1813904
9. [9]
  J.M. Giltnane, K.E. Hutchinson, T.P. Stricker, et al., Sci. Transl. Med. 9 (2017) eaai7993. doi: 10.1126/scitranslmed.aai7993
10. [10]
  P. Razavi, M.T. Chang, G. Xu, et al., Cancer Cell 34 (2018) 427-438.e6. doi: 10.1016/j.ccell.2018.08.008
11. [11]
  H.J. Burstein, N. Engl. J. Med. 383 (2020) 2557–2570. doi: 10.1056/nejmra1307118
12. [12]
  A.C. Tecalco-Cruz, I.A. Perez-Alvarado, J.O. Ramirez-Jarquin, L. Rocha-Zavaleta, Cell. Signal. 34 (2017) 121–132. doi: 10.1016/j.cellsig.2017.03.011
13. [13]
  B.V. Phillips-Farfán, B.G. Quintanar, R. Reyes, A. Fernández-Guasti, Physiol. Behav. 268 (2023) 114237. doi: 10.1016/j.physbeh.2023.114237
14. [14]
  C.N. Haines, S.E. Wardell, D.P. McDonnell, Essays Biochem. 65 (2021) 985–1001. doi: 10.1042/ebc20200174
15. [15]
  D.P. McDonnell, S.E. Wardell, C.Y. Chang, J.D. Norris, J. Clin. Oncol. 39 (2021) 1383–1388. doi: 10.1200/jco.20.03565
16. [16]
  V.C. Jordan, Eur. J. Cancer 44 (2008) 30–38. doi: 10.1016/j.ejca.2007.11.002
17. [17]
  D.J. Kojetin, T.P. Burris, E.V. Jensen, S.A. Khan, Endocr. Relat. Cancer 15 (2008) 851–870. doi: 10.1677/ERC-07-0281
18. [18]
  S. Damodaran, C.C. O'Sullivan, A. Elkhanany, et al., Ann. Oncol. 34 (2023) 1131–1140. doi: 10.1016/j.annonc.2023.09.3103
19. [19]
  E.R. Simpson, S.R. Davis, Endocrinology 142 (2001) 4589–4594. doi: 10.1210/endo.142.11.8547
20. [20]
  T.V. Augusto, G. Correia-da-Silva, C.M.P. Rodrigues, et al., Endocr. Relat. Cancer 25 (2018) R283–R301. doi: 10.1530/erc-17-0425
21. [21]
  A. Gennari, F. Andre, C.H. Barrios, et al., Ann. Oncol. 32 (2021) 1475–1495. doi: 10.1016/j.annonc.2021.09.019
22. [22]
  A.L. Wijayaratne, D.P. McDonnell, J. Biol. Chem. 276 (2001) 35684–35692. doi: 10.1074/jbc.M101097200
23. [23]
  G. Jane, Z. Wei, H. Marc, et al., Cell 178 (2019) 949-963.e18. doi: 10.1016/j.cell.2019.06.026
24. [24]
  T. Bihani, H.K. Patel, H. Arlt, et al., Clin. Cancer Res. 23 (2017) 4793–4804. doi: 10.1158/1078-0432.CCR-16-2561
25. [25]
  S.M. Hoy, Drugs 83 (2023) 555–561. doi: 10.1007/s40265-023-01861-0
26. [26]
  D.P. Bondeson, A. Mares, I.E.D. Smith, et al., Nat. Chem. Biol. 11 (2015) 611–617. doi: 10.1038/nchembio.1858
27. [27]
  L.B. Snyder, J.J. Flanagan, Y. Qian, et al., Cancer Res. 81 (2021) 44. doi: 10.1158/1538-7445.am2021-44
28. [28]
  W. He, H. Zhang, L. Perkins, et al., Cancer Res. 81 (2021) PS18-09. doi: 10.1158/0008-5472.CAN-20-2245
29. [29]
  M. Bekes, D.R. Langley, C.M. Crews, Nat. Rev. Drug. Discov. 21 (2022) 181–200. doi: 10.1038/s41573-021-00371-6
30. [30]
  E. Ferraro, E.M. Walsh, J.J. Tao, et al., Cancer Treat. Rev. 109 (2022) 102432. doi: 10.1016/j.ctrv.2022.102432
31. [31]
  F. Rasha, M. Sharma, K. Pruitt, Mol. Cell. Endocrinol. 532 (2021) 111322. doi: 10.1016/j.mce.2021.111322
32. [32]
  R. Jeselsohn, G. Buchwalter, C. De Angelis, et al., Nat. Rev. Clin. Oncol. 12 (2015) 573–583. doi: 10.1038/nrclinonc.2015.117
33. [33]
  A.B. Hanker, D.R. Sudhan, C.L. Arteaga, Cancer Cell 37 (2020) 496–513. doi: 10.1016/j.ccell.2020.03.009
34. [34]
  X. Yang, D.L. Phillips, A.T. Ferguson, et al., Cancer Res. 61 (2001) 7025–7029.
35. [35]
  M. Palaniappan, Biomedicines 12 (2024) 2700. doi: 10.3390/biomedicines12122700
36. [36]
  J. Rinath, Y. Roman, B. Gilles, et al., Clin. Cancer Res. 20 (2014) 1757–1767. doi: 10.1158/1078-0432.CCR-13-2332
37. [37]
  H. Kurokawa, A.E. Lenferink, J.F. Simpson, et al., Cancer Res. 60 (2000) 5887–5894.
38. [38]
  L. Formisano, K.M. Stauffer, C.D. Young, et al., Clin. Cancer Res. 23 (2017) 6138–6150. doi: 10.1158/1078-0432.CCR-17-1232
39. [39]
  T.W. Miller, B.T. Hennessy, A.M. Gonzalez-Angulo, et al., J. Clin. Invest. 120 (2010) 2406–2413. doi: 10.1172/JCI41680
40. [40]
  F. Bertucci, C.K.Y. Ng, A. Patsouris, et al., Nature 569 (2019) 560–564. doi: 10.1038/s41586-019-1056-z
41. [41]
  C. Fribbens, I. Garcia Murillas, M. Beaney, et al., Ann. Oncol. 29 (2018) 145–153. doi: 10.1093/annonc/mdx483
42. [42]
  R.J. Sullivan, J.R. Infante, F. Janku, et al., Cancer Discov. 8 (2018) 184–195. doi: 10.1158/2159-8290.cd-17-1119
43. [43]
  J. Huang, L. Zheng, Z. Sun, J. Li, Int. J. Mol. Med. 50 (2022) 128. doi: 10.3892/ijmm.2022.5184
44. [44]
  L.M. Spring, S.A. Wander, F. Andre, et al., Lancet 395 (2020) 817–827. doi: 10.1016/S0140-6736(20)30165-3
45. [45]
  H. Hu, W. Zhang, L. Lei, et al., Chin. Chem. Lett. 35 (2024) 108765. doi: 10.1016/j.cclet.2023.108765
46. [46]
  Y. Xu, L. Huang, Y. Bi, et al., Chin. Chem. Lett. 34 (2023) 107719. doi: 10.1016/j.cclet.2022.07.062
47. [47]
  X. Zhang, X. Liu, L. Qin, et al., Chin. Chem. Lett. 34 (2023) 107618. doi: 10.1016/j.cclet.2022.06.041
48. [48]
  H. Ikeda, K. Kawase, T. Nishi, et al., Nature 638 (2025) 225–236. doi: 10.1038/s41586-024-08439-0
49. [49]
  T. Mukohara, Y.H. Park, D. Sommerhalder, et al., Nat. Med. 30 (2024) 2242–2250. doi: 10.1038/s41591-024-03060-0
50. [50]
  Y.J. Choi, X. Li, P. Hydbring, et al., Cancer Cell 22 (2012) 438–451. doi: 10.1016/j.ccr.2012.09.015
51. [51]
  R.M. Zwijsen, E. Wientjens, R. Klompmaker, et al., Cell 88 (1997) 405–415. doi: 10.1016/S0092-8674(00)81879-6
52. [52]
  S.C. Scott, S.S. Lee, J. Abraham, Semin. Oncol. 44 (2017) 385–394. doi: 10.1053/j.seminoncol.2018.01.006
53. [53]
  P.L. Toogood, P.J. Harvey, J.T. Repine, et al., J. Med. Chem. 48 (2005) 2388–2406. doi: 10.1021/jm049354h
54. [54]
  L. Malorni, G. Curigliano, A.M. Minisini, et al., Ann. Oncol. 29 (2018) 1748–1754. doi: 10.1093/annonc/mdy214
55. [55]
  R.S. Finn, J.P. Crown, I. Lang, et al., Lancet Oncol. 16 (2015) 25–35. doi: 10.1016/S1470-2045(14)71159-3
56. [56]
  R.S. Finn, M. Martin, H.S. Rugo, et al., N. Engl. J. Med. 375 (2016) 1925–1936. doi: 10.1056/NEJMoa1607303
57. [57]
  M. Cristofanilli, N.C. Turner, I. Bondarenko, et al., Lancet Oncol. 17 (2016) 425–439. doi: 10.1016/S1470-2045(15)00613-0
58. [58]
  N.C. Turner, D.J. Slamon, J. Ro, et al., N. Engl. J. Med. 379 (2018) 1926–1936. doi: 10.1056/nejmoa1810527
59. [59]
  S.E. Nunnery, I.A. Mayer, Drugs 80 (2020) 1685–1697. doi: 10.1007/s40265-020-01394-w
60. [60]
  P. du Rusquec, C. Blonz, J.S. Frenel, M. Campone, Ther. Adv. Med. Oncol. 12 (2020) 1758835920940939. doi: 10.1177/1758835920940939
61. [61]
  N. Vasan, E. Toska, M. Scaltriti, Ann. Oncol. 30 (2019) x3–x11. doi: 10.1093/annonc/mdz281
62. [62]
  E. Geuna, A. Milani, R. Martinello, et al., Expert Opin. Investig. Drugs 24 (2015) 421–431. doi: 10.1517/13543784.2015.1008132
63. [63]
  J. Baselga, S. -A. Im, H. Iwata, et al., Lancet Oncol. 18 (2017) 904–916. doi: 10.1016/S1470-2045(17)30376-5
64. [64]
  P. Furet, V. Guagnano, R.A. Fairhurst, et al., Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748. doi: 10.1016/j.bmcl.2013.05.007
65. [65]
  H.S. Rugo, F. Andre, T. Yamashita, et al., Ann. Oncol. 31 (2020) 1001–1010. doi: 10.1016/j.annonc.2020.05.001
66. [66]
  S.M. Tolaney, Y.H. Im, E. Calvo, et al., Clin. Cancer Res. 27 (2021) 418–428. doi: 10.1158/1078-0432.ccr-20-0645
67. [67]
  I.A. Mayer, V.G. Abramson, L. Formisano, et al., Clin. Cancer Res. 23 (2017) 26–34.
68. [68]
  C.X. Ma, C. Sanchez, F. Gao, et al., Clin. Cancer Res. 22 (2016) 2650–2658. doi: 10.1158/1078-0432.CCR-15-2160
69. [69]
  C.X. Ma, V. Suman, M.P. Goetz, et al., Clin. Cancer Res. 23 (2017) 6823–6832. doi: 10.1158/1078-0432.CCR-17-1260
70. [70]
  M. Royce, T. Bachelot, C. Villanueva, et al., JAMA Oncol. 4 (2018) 977–984. doi: 10.1001/jamaoncol.2018.0060
71. [71]
  H. Tesch, O. Stoetzer, T. Decker, et al., Int. J. Cancer 144 (2019) 877–885. doi: 10.1002/ijc.31738
72. [72]
  S.M. Guichard, J. Curwen, T. Bihani, et al., Mol. Cancer Ther. 14 (2015) 2508–2518. doi: 10.1158/1535-7163.MCT-15-0365
73. [73]
  S. Pancholi, M.F. Leal, R. Ribas, et al., Breast Cancer Res. 21 (2019) 135. doi: 10.1186/s13058-019-1222-0
74. [74]
  J.A. Garcia-Saenz, N. Martinez-Janez, R. Cubedo, et al., Clin. Cancer Res. 28 (2022) 1107–1116. doi: 10.1158/1078-0432.ccr-21-2652
75. [75]
  R. Tohkayomatee, S. Reabroi, D. Tungmunnithum, et al., Molecules 27 (2022) 248.
76. [76]
  R. Margueron, V. Duong, A. Castet, V. Cavailles, Biochem. Pharmacol. 68 (2004) 1239–1246. doi: 10.1016/j.bcp.2004.04.031
77. [77]
  T. Kovács, E. Szabó-Meleg, I.M. Ábrahám, Int. J. Mol. Sci. 21 (2020) 3177. doi: 10.3390/ijms21093177
78. [78]
  Z. Cui, M. Xie, Z. Wu, Y. Shi, Med. Sci. Monit. 24 (2018) 2456–2464. doi: 10.12659/msm.906576
79. [79]
  J.M. Craig, T.H. Turner, J.C. Harrell, C.V. Clevenger, Endocrinology 162 (2021) bqab036. doi: 10.1210/endocr/bqab036
80. [80]
  P. Raha, S. Thomas, K.T. Thurn, et al., Breast Cancer Res. 17 (2015) 26. doi: 10.1186/s13058-015-0533-z
81. [81]
  C. Tang, C. Li, S. Zhang, et al., J. Med. Chem. 58 (2015) 4550–4572. doi: 10.1021/acs.jmedchem.5b00099
82. [82]
  G. Luo, X. Lin, S. Ren, et al., Eur. J. Med. Chem. 226 (2021) 113870. doi: 10.1016/j.ejmech.2021.113870
83. [83]
  S. Xiong, X. Wang, M. Zhu, et al., Bioorg Chem 134 (2023) 106459. doi: 10.1016/j.bioorg.2023.106459
84. [84]
  P.N. Munster, K.T. Thurn, S. Thomas, et al., Br. J. Cancer 104 (2011) 1828–1835. doi: 10.1038/bjc.2011.156
85. [85]
  Z. Jiang, W. Li, X. Hu, et al., Lancet Oncol. 20 (2019) 806–815. doi: 10.1016/S1470-2045(19)30164-0
86. [86]
  L. Xu, W. Jiang, W. Li, et al., Exp. Ther. Med. 24 (2022) 575. doi: 10.3892/etm.2022.11512
87. [87]
  P.G. Alluri, I.A. Asangani, A.M. Chinnaiyan, Cell. Res. 24 (2014) 899–900. doi: 10.1038/cr.2014.90
88. [88]
  E. García-Oliver, C. Ramus, J. Perot, et al., PLoS Genet. 13 (2017) e1006541. doi: 10.1371/journal.pgen.1006541
89. [89]
  A.J. Stonestrom, S.C. Hsu, M.T. Werner, G.A. Blobel, Drug Discov. Today Technol. 19 (2016) 23–28. doi: 10.1016/j.ddtec.2016.05.004
90. [90]
  Q. Feng, Z. Zhang, M.J. Shea, et al., Cell Res. 24 (2014) 809–819. doi: 10.1038/cr.2014.71
91. [91]
  J. Hilton, M. Cristea, S. Postel-Vinay, et al., Cancers (Basel) 14 (2022) 4079. doi: 10.3390/cancers14174079
92. [92]
  S.A. Piha-Paul, J.C. Sachdev, M. Barve, et al., Clin. Cancer Res. 25 (2019) 6309–6319. doi: 10.1158/1078-0432.ccr-19-0578
93. [93]
  E. Hervouet, P.F. Cartron, M. Jouvenot, R. Delage-Mourroux, Epigenetics 8 (2013) 237–245. doi: 10.4161/epi.23790
94. [94]
  Y. Shi, F. Lan, C. Matson, et al., Cell 119 (2004) 941–953. doi: 10.1016/j.cell.2004.12.012
95. [95]
  R.J. Klose, E.M. Kallin, Y. Zhang, Nat. Rev. Genet. 7 (2006) 715–727. doi: 10.1038/nrg1945
96. [96]
  M.A. Bennesch, G. Segala, D. Wider, D. Picard, Nucleic Acids Res. 44 (2016) 8655–8670. doi: 10.1093/nar/gkw522
97. [97]
  M. He, W. Ning, Z. Hu, et al., Eur. J. Med. Chem. 195 (2020) 112281. doi: 10.1016/j.ejmech.2020.112281
98. [98]
  H.P. Dhakal, B. Naume, M. Synnestvedt, et al., Histopathology 61 (2012) 350–364. doi: 10.1111/j.1365-2559.2012.04223.x
99. [99]
  Z. Madak-Erdogan, M. Lupien, F. Stossi, et al., Mol. Cell. Biol. 31 (2011) 226–236. doi: 10.1128/MCB.00821-10
100. [100]
  Z. Tang, C. Wu, T. Wang, et al., Eur. J. Med. Chem. 118 (2016) 328–339. doi: 10.1016/j.ejmech.2016.04.029
101. [101]
  G. Luo, X. Li, G. Zhang, et al., Eur. J. Med. Chem. 140 (2017) 252–273. doi: 10.1016/j.ejmech.2017.09.015
102. [102]
  X. Li, C. Wu, X. Lin, et al., Eur. J. Med. Chem. 161 (2019) 445–455. doi: 10.1159/000502203
103. [103]
  M. Jordan, Curr. Med. Chem. Anticancer Agents 2 (2002) 1–17. doi: 10.2174/1568011023353859
104. [104]
  N.M. O'Boyle, J.K. Pollock, M. Carr, et al., J. Med. Chem. 57 (2014) 9370–9382. doi: 10.1021/jm500670d
105. [105]
  X. Deng, X. Deng, W. Ning, et al., J. Med. Chem. 66 (2023) 11094–11117. doi: 10.1021/acs.jmedchem.3c00465
106. [106]
  W.M. Swetzig, J. Wang, G.M. Das, Oncotarget 7 (2016) 16049–16069. doi: 10.18632/oncotarget.7533
107. [107]
  N. Portman, H.H. Milioli, S. Alexandrou, et al., Breast Cancer Res. 22 (2020) 87. doi: 10.1186/s13058-020-01318-2
108. [108]
  F. Acconcia, C.J. Barnes, R. Kumar, Endocrinology. 147 (2006) 1203–1212. doi: 10.1210/en.2005-1293
109. [109]
  L.F. Hennequin, J. Allen, J. Breed, et al., J. Med. Chem. 49 (2006) 6465–6488. doi: 10.1021/jm060434q
110. [110]
  S. Hiscox, N.J. Jordan, C. Smith, et al., Breast Cancer Res. Treat. 115 (2009) 57–67. doi: 10.1007/s10549-008-0058-6
111. [111]
  Y. Zhou, S. Eppenberger-Castori, U. Eppenberger, C.C. Benz, Endocr. Relat. Cancer 12 Suppl 1 (2005) S37–S46. doi: 10.1677/erc.1.00977
112. [112]
  S.C. Baumgarten, J. Frasor, Mol. Endocrinol. 26 (2012) 360–371. doi: 10.1210/me.2011-1302
113. [113]
  W. Ning, Z. Hu, C. Tang, et al., J. Med. Chem. 61 (2018) 8155–8173. doi: 10.1021/acs.jmedchem.8b00224
114. [114]
  S.K. Kim, J.W. Yang, M.R. Kim, et al., Free Radic. Biol. Med. 45 (2008) 537–546. doi: 10.1016/j.freeradbiomed.2008.05.011
115. [115]
  A. Ghanem, A.M. Melzer, E. Zaal, et al., Free Radic. Biol. Med. 163 (2021) 196–209. doi: 10.1016/j.freeradbiomed.2020.12.012
116. [116]
  Z. Wu, J. Wu, Q. Zhao, et al., Clin. Transl. Oncol. 22 (2020) 631–646. doi: 10.1007/s12094-019-02187-8
117. [117]
  X. Deng, B. Xie, Q. Li, et al., J. Med. Chem. 65 (2022) 7993–8010. doi: 10.1021/acs.jmedchem.2c00525
118. [118]
  A.K. Rao, Y.S. Ziegler, I.X. McLeod, et al., J. Mol. Endocrinol. 43 (2009) 251–261. doi: 10.1677/JME-09-0053
119. [119]
  B.J. Deroo, S.C. Hewitt, S.D. Peddada, K.S. Korach, Endocrinology 145 (2004) 5485–5492. doi: 10.1210/en.2004-0471
120. [120]
  Y. Lu, X. Sheng, C. Liu, et al., Pharmacol. Res. 190 (2023) 106731. doi: 10.1016/j.phrs.2023.106731
121. [121]
  L. Xin, C. Wang, Y. Cheng, et al., J. Med. Chem. 67 (2024) 8913–8931. doi: 10.1021/acs.jmedchem.4c00196
1. [1]
  Lulu He , Le Wang , Zhen He , Yiqian Yang , Cheng Heng Pang , Aiguo Wu , Bencan Tang , Juan Li . An imine-linked covalent organic framework with intrinsic photo-induced mitochondrial regulation for breast cancer therapy. Chinese Chemical Letters, 2025, 36(9): 110717-. doi: 10.1016/j.cclet.2024.110717
2. [2]
  Yanyan Yin , Jun Guo , Shuo Zhang , Meng Xu , Yun Fu , Mengyi Zhang , Zhipeng Ma , Jiajia Ji , Siyuan Wu , Jinjie Zhang , Jianbo Li , Lei Wang . Research progress and prospect of tumor nanovaccine combination therapy strategy. Chinese Chemical Letters, 2025, 36(10): 110771-. doi: 10.1016/j.cclet.2024.110771
3. [3]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
4. [4]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
5. [5]
  Hao Sun , Shengke Li , Qian Liu , Minzan Zuo , Xueqi Tian , Kaiya Wang , Xiao-Yu Hu . Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy. Chinese Chemical Letters, 2025, 36(3): 109999-. doi: 10.1016/j.cclet.2024.109999
6. [6]
  Jiangshan Xu , Weifei Zhang , Zhengwen Cai , Yong Li , Long Bai , Shaojingya Gao , Qiang Sun , Yunfeng Lin . Tetrahedron DNA nanostructure/iron-based nanomaterials for combined tumor therapy. Chinese Chemical Letters, 2024, 35(11): 109620-. doi: 10.1016/j.cclet.2024.109620
7. [7]
  Keqiang Shi , Xiujuan Hong , Dongyan Xu , Tao Pan , Huiwen Wang , Hongru Feng , Cheng Guo , Yuanjiang Pan . Analysis of RNA modifications in peripheral white blood cells from breast cancer patients by mass spectrometry. Chinese Chemical Letters, 2025, 36(3): 110079-. doi: 10.1016/j.cclet.2024.110079
8. [8]
  Xinyue Han , Yunhan Yang , Jiayin Lu , Yuxiang Lin , Dongxue Zhang , Ling Lin , Liang Qiao . Efficient serum lipids profiling by TiO₂-dopamin-assisted MALDI-TOF MS for breast cancer detection. Chinese Chemical Letters, 2025, 36(5): 110183-. doi: 10.1016/j.cclet.2024.110183
9. [9]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
10. [10]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
11. [11]
  Peng Gao , Yuanyuan Chen , Qianlin He , Xue Liu , Echuan Tan , Zhiqiang Yu , Hui Wang . Highly efficient adoptive cell therapy of metastatic triple negative breast cancer with bioactive covalent organic framework-engineered macrophages. Chinese Chemical Letters, 2025, 36(8): 110585-. doi: 10.1016/j.cclet.2024.110585
12. [12]
  Li Li , Jiale Wen , Xiaojun Zhang , Shuwen Fu , Zixuan Chen , Kai Huang , Luyue Fang , Tinghe Zhao , Peipei Zhang , Xingshu Li . A near-infrared naphthalocyanine photosensitizer with superior light absorption and renal clearance for type-Ⅰ photodynamic and photothermal combination therapy. Chinese Chemical Letters, 2025, 36(6): 110290-. doi: 10.1016/j.cclet.2024.110290
13. [13]
  Li Fu , Ziye Su , Shuyang Wu , Yanfen Cheng , Chuan Hu , Jinming Zhang . Redox-responsive hyaluronic acid-celastrol prodrug micelles with glycyrrhetinic acid co-delivery for tumor combination therapy. Chinese Chemical Letters, 2025, 36(5): 110227-. doi: 10.1016/j.cclet.2024.110227
14. [14]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
15. [15]
  Zhaoyong Kang , Shen Li , Yan Li , Jingfeng Song , Yangrui Peng , Yihua Chen . Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024). Chinese Chemical Letters, 2025, 36(7): 110447-. doi: 10.1016/j.cclet.2024.110447
16. [16]
  Qinyu Zhao , Yunchao Zhao , Songjing Zhong , Zhaoyang Yue , Zhuoheng Jiang , Shaobo Wang , Quanhong Hu , Shuncheng Yao , Kaikai Wen , Linlin Li . Urchin-like piezoelectric ZnSnO₃/Cu₃P p-n heterojunction for enhanced cancer sonodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109644-. doi: 10.1016/j.cclet.2024.109644
17. [17]
  Xiongbo Song , Jinwen Xiao , Juan Wu , Li Sun , Long Chen . Decellularized amniotic membrane promotes the anti-inflammatory response of macrophages via PI3K/AKT/HIF-1α pathway. Chinese Chemical Letters, 2025, 36(1): 109844-. doi: 10.1016/j.cclet.2024.109844
18. [18]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
19. [19]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
20. [20]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(78)
HTML views(0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142